D. E. Shaw & Co., Inc. Athenex, Inc. Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.41 - $0.91 $12,057 - $26,762	29,409 New	29,409 $12,000
Q1 2021 May 17, 2021	SELL	$4.08 - $14.75 $224,995 - $813,403	-55,146 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$11.06 - $14.01 $609,914 - $772,595	55,146 New	55,146 $610,000
Q3 2020 Nov 16, 2020	SELL	$10.26 - $14.55 $176,954 - $250,943	-17,247 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$7.11 - $13.76 $182,975 - $354,113	-25,735 Reduced 59.87%	17,247 $237,000
Q1 2020 May 15, 2020	BUY	$5.71 - $15.85 $96,350 - $267,452	16,874 Added 64.63%	42,982 $333,000
Q4 2019 Feb 14, 2020	SELL	$9.6 - $17.75 $1.8 Million - $3.33 Million	-187,450 Reduced 87.77%	26,108 $399,000
Q3 2019 Nov 14, 2019	BUY	$12.16 - $21.0 $2.29 Million - $3.96 Million	188,584 Added 755.12%	213,558 $2.6 Million
Q2 2019 Aug 14, 2019	BUY	$9.44 - $19.8 $235,754 - $494,485	24,974 New	24,974 $494,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.